<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30377210</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>31</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">2045-4368</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>26</Day>                    </PubDate>                </JournalIssue>                <Title>BMJ supportive &amp; palliative care</Title>                <ISOAbbreviation>BMJ Support Palliat Care</ISOAbbreviation>            </Journal>            <ArticleTitle>Rose geranium in sesame oil nasal spray: a treatment for nasal vestibulitis?</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">bmjspcare-2018-001569</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjspcare-2018-001569</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">As a rose geranium in sesame oil spray product has been anecdotally noted to improve nasal vestibulitis symptoms, this study was designed to assess whether patients with nasal vestibulitis associated with cancer-directed therapy experienced symptomatic improvements from it.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Patients with breast cancer, prescribed rose geranium nasal spray, were identified by looking at pharmacy records and patient diagnosis at Mayo Clinic Rochester. Patient medical information, as well as documentation of symptoms, were gleaned from medical charts. Questionnaires were sent to patients regarding their experiences.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 40 patients with breast cancer who were prescribed rose geranium nasal spray, 100% were receiving cancer-directed therapy: 58 % were receiving taxane chemotherapy; others received a variety of cytotoxic and targeted therapy treatments. Twenty patients who had used the spray product returned surveys. Patient-reported nasal symptoms included bleeding (90%), dryness (86%), pain (81%), scabbing (67%) and sores (52%); patients consistently reported symptoms at a higher proportion than did healthcare providers. All patients who used the rose geranium nasal spray reported symptomatic benefit; one reported a little benefit, 11 (55%) reported moderate benefit and eight (40%) reported dramatic or complete resolution of symptoms. The therapy was well tolerated in most patients.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Rose geranium in sesame oil nasal spray appears to improve patient-reported nasal symptoms associated with cancer-directed therapy.</AbstractText>                <CopyrightInformation>Â© Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Cathcart-Rake</LastName>                    <ForeName>Elizabeth J</ForeName>                    <Initials>EJ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA cathcart-rake.elizabeth@mayo.edu.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Smith</LastName>                    <ForeName>Deanne</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zahrieh</LastName>                    <ForeName>David</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Health Sciences Research, Cancer Statistics, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Loprinzi</LastName>                    <ForeName>Charles L</ForeName>                    <Initials>CL</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>26</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>BMJ Support Palliat Care</MedlineTA>            <NlmUniqueID>101565123</NlmUniqueID>            <ISSNLinking>2045-435X</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">nasal spray</Keyword>            <Keyword MajorTopicYN="N">nasal vestibulitis</Keyword>            <Keyword MajorTopicYN="N">toxicity of chemotherapy</Keyword>            <Keyword MajorTopicYN="N">toxicity of targeted therapy</Keyword>        </KeywordList>        <CoiStatement>Competing interests: EC-R, DZ and DS have nothing to disclose. CLL discloses the following: Pfizer, Theravance, Competitive Technologies, GOMC Co Ltd, Acetylon and Janssen have all, in the past, provided funds and/or materials to Mayo for research work that he has done, not directly related to the present publication. He has also consulted for the following companies: PledPharma, Lpath, Mundipharma and Insys for consultations not directly related to the present publication.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>14</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>29</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30377210</ArticleId>            <ArticleId IdType="pii">bmjspcare-2018-001569</ArticleId>            <ArticleId IdType="doi">10.1136/bmjspcare-2018-001569</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>